The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Giuseppe Giaccone

Department of Medical Oncology

VU University Medical Center

Amsterdam

Netherlands

[email]@vumc.nl

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands. 2002 - 2007
  • Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, Netherlands. 2004 - 2005
  • Free University Hospital, Amsterdam, Netherlands. 2002

References

  1. The potential of antiangiogenic therapy in non-small cell lung cancer. Giaccone, G. Clin. Cancer Res. (2007) [Pubmed]
  2. Systemic treatment of malignant thymoma: a decade experience at a single institution. Giaccone, G., Wilmink, H., Paul, M.A., van der Valk, P. Am. J. Clin. Oncol. (2006) [Pubmed]
  3. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Giaccone, G., Gallegos Ruiz, M., Le Chevalier, T., Thatcher, N., Smit, E., Rodriguez, J.A., Janne, P., Oulid-Aissa, D., Soria, J.C. Clin. Cancer Res. (2006) [Pubmed]
  4. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Giaccone, G. Ann. Oncol. (2005) [Pubmed]
  5. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. Giaccone, G. J. Clin. Oncol. (2005) [Pubmed]
  6. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Janmaat, M.L., Rodriguez, J.A., Jimeno, J., Kruyt, F.A., Giaccone, G. Mol. Pharmacol. (2005) [Pubmed]
  7. Lung cancer. Giaccone, G., Smit, E. Cancer. Chemother. Biol. Response. Modif (2005) [Pubmed]
  8. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Giaccone, G., Debruyne, C., Felip, E., Chapman, P.B., Grant, S.C., Millward, M., Thiberville, L., D'addario, G., Coens, C., Rome, L.S., Zatloukal, P., Masso, O., Legrand, C. J. Clin. Oncol. (2005) [Pubmed]
  9. EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Giaccone, G. Nature Clinical Practice. Oncology (2005) [Pubmed]
  10. EGFR inhibitors: what have we learned from the treatment of lung cancer?. Giaccone, G., Rodriguez, J.A. Nature Clinical Practice. Oncology (2005) [Pubmed]
  11. Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Giaccone, G. Future. Oncology. (london,. England) (2005) [Pubmed]
  12. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. Giaccone, G., Herbst, R.S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R.B., Schiller, J.H., Von Pawel, J., Pluzanska, A., Gatzemeier, U., Grous, J., Ochs, J.S., Averbuch, S.D., Wolf, M.K., Rennie, P., Fandi, A., Johnson, D.H. J. Clin. Oncol. (2004) [Pubmed]
  13. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Giaccone, G., Smit, E.F., de Jonge, M., Dansin, E., Briasoulis, E., Ardizzoni, A., Douillard, J.Y., Spaeth, D., Lacombe, D., Baron, B., Bachmann, P., Fumoleau, P. Eur. J. Cancer (2004) [Pubmed]
  14. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Giaccone, G., González-Larriba, J.L., van Oosterom, A.T., Alfonso, R., Smit, E.F., Martens, M., Peters, G.J., van der Vijgh, W.J., Smith, R., Averbuch, S., Fandi, A. Ann. Oncol. (2004) [Pubmed]
  15. Lung cancer. Giaccone, G., Smit, E. Cancer. Chemother. Biol. Response. Modif (2003) [Pubmed]
  16. Clinical impact of novel treatment strategies. Giaccone, G. Oncogene (2002) [Pubmed]
  17. Targeted therapy in non-small cell lung cancer. Giaccone, G. Lung. Cancer (2002) [Pubmed]
  18. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Giaccone, G., Punt, C.J., Ando, Y., Ruijter, R., Nishi, N., Peters, M., von Blomberg, B.M., Scheper, R.J., van der Vliet, H.J., van den Eertwegh, A.J., Roelvink, M., Beijnen, J., Zwierzina, H., Pinedo, H.M. Clin. Cancer Res. (2002) [Pubmed]
  19. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Giaccone, G., O'Brien, M.E., Byrne, M.J., Bard, M., Kaukel, E., Smit, B. Eur. J. Cancer (2002) [Pubmed]
  20. Update on the systemic treatment of lung cancer. Giaccone, G., Smit, E.F. Cancer. Chemother. Biol. Response. Modif (2002) [Pubmed]
 
WikiGenes - Universities